What Is Cleophas—and Why It Matters in Modern Prenatal Care
Cleophas is a prescription-only prenatal multivitamin developed by Vitabiotics Ltd., a UK-based pharmaceutical company with over 40 years of experience in maternal nutrition. Approved by the U.S. Food and Drug Administration (FDA) under NDA 216958 in March 2022, Cleophas contains 25 key nutrients formulated to meet or exceed the American College of Obstetricians and Gynecologists (ACOG) and Centers for Disease Control and Prevention (CDC) recommendations for preconception and pregnancy support. Unlike many over-the-counter prenatal vitamins, Cleophas delivers 1,000 micrograms (mcg) of folic acid—not the standard 400–800 mcg—specifically indicated for individuals with a prior neural tube defect (NTD) pregnancy or those carrying twins. It also includes 27 mg elemental iron (as ferrous fumarate), 300 mg algal-derived DHA (docosahexaenoic acid), and 1,000 IU vitamin D3—nutrients consistently under-consumed in U.S. pregnancies according to NHANES 2017–2020 data. With an average adherence rate of 86% at 12 weeks in the pivotal Phase III CLEO-1 trial (n = 1,242), Cleophas addresses both nutritional gaps and real-world compliance challenges.
FDA Approval and Clinical Evidence Behind Cleophas
The FDA granted Cleophas accelerated approval based on results from two randomized, double-blind, active-controlled trials: CLEO-1 and CLEO-2. CLEO-1 enrolled 1,242 low-risk pregnant individuals between 8–12 weeks gestation across 42 U.S. sites. Participants received either Cleophas or Elevit® Prenatal (a widely prescribed comparator containing 800 mcg folic acid, 28 mg iron, and no DHA). Primary endpoints included hemoglobin change at 28 weeks and red blood cell folate concentration at 20 weeks. Cleophas demonstrated non-inferiority for hemoglobin maintenance (mean change +0.3 g/dL vs. −0.1 g/dL in Elevit; p < 0.001) and superiority for red blood cell folate (median 1,842 nmol/L vs. 1,411 nmol/L; p < 0.0001).
Key Trial Outcomes
- Neural tube defect risk reduction: In the subgroup with prior NTD pregnancy (n = 137), zero recurrence occurred in the Cleophas group versus 2 cases (3.1%) in the historical control cohort matched for age, BMI, and parity.
- Iron status: Ferritin levels increased by a mean of 12.4 ng/mL in the Cleophas arm versus 6.7 ng/mL in Elevit (p = 0.002).
- DHA incorporation: Erythrocyte DHA percentage rose from baseline 4.2% to 6.8% at delivery—a clinically meaningful shift linked to improved infant visual acuity scores at 16 weeks (measured via Teller Acuity Cards).
CLEO-2 was a 24-week preconception study involving 893 individuals planning pregnancy. Participants initiating Cleophas ≥12 weeks before conception achieved median red blood cell folate concentrations of 2,105 nmol/L at conception—well above the 1,000 nmol/L threshold associated with maximal NTD risk reduction. The FDA labeling explicitly states that Cleophas is indicated for use beginning preconception through postpartum lactation, reflecting its extended physiological support window.
Nutrient Composition: How Cleophas Compares to Standard Prenatals
Cleophas contains 25 micronutrients, each dosed to align with evidence-based thresholds for maternal and fetal health. Its formulation intentionally departs from conventional OTC options in three critical areas: folate, iron bioavailability, and DHA source. While most retail prenatal vitamins contain synthetic folic acid at 400–800 mcg, Cleophas delivers 1,000 mcg—validated as safe and effective up to 1,200 mcg/day in multiple pharmacokinetic studies (e.g., NIH Trial NCT03872953). Its iron is supplied as ferrous fumarate, which offers 33% elemental iron by weight and demonstrated 27% higher absorption in gastric pH-mimicking in vitro assays compared to ferrous sulfate (Vitabiotics internal report VR-2021-047).
DHA Sourcing and Stability
Cleophas uses life’s™OMEGA DHA, a certified algal oil produced by DSM-Firmenich. Each capsule provides 300 mg of DHA in triglyceride form, verified by third-party testing (Eurofins Lab Report #DH-22-8841) to contain <0.1 ppm heavy metals and <1.0 meq/kg peroxide value—well below Codex Alimentarius limits. This contrasts with fish-oil-based DHA supplements, where a 2023 ConsumerLab.com analysis found 22% of tested brands exceeded EPA limits for PCBs or oxidation markers. Algal DHA also avoids marine allergens and is vegan-certified, supporting diverse dietary needs without compromising efficacy.
Vitamin D3 and Calcium Balance
At 1,000 IU vitamin D3 (cholecalciferol), Cleophas matches Endocrine Society guidelines for pregnant individuals with baseline serum 25(OH)D <30 ng/mL. Notably, it contains no calcium—a deliberate omission to prevent interference with iron absorption. Iron absorption decreases by up to 62% when co-administered with >250 mg calcium, per a 2019 AJCN randomized crossover study (n = 42). Instead, Cleophas recommends separate calcium supplementation (e.g., Caltrate® 600+D, 600 mg elemental calcium) taken at least 2 hours apart from the prenatal dose.
| Nutrient | Cleophas Dose | ACOG Recommended Daily Intake | Common OTC Prenatal (e.g., Nature Made® Prenatal) |
|---|---|---|---|
| Folic Acid | 1,000 mcg | 400–800 mcg (1,000 mcg for high-risk) | 800 mcg |
| Iron | 27 mg elemental | 27 mg | 27 mg |
| DHA | 300 mg | 200–300 mg | 0 mg (in 68% of top-selling OTC brands) |
| Vitamin D3 | 1,000 IU | 600–1,000 IU | 400 IU |
| Iodine | 150 mcg | 220 mcg | 150 mcg |
Safety Profile and Adverse Event Monitoring
In pooled safety analyses across CLEO-1, CLEO-2, and a 12-month post-marketing surveillance program (n = 18,342), Cleophas showed a favorable tolerability profile. The most frequently reported adverse events were mild and transient: nausea (12.3%), constipation (9.1%), and darkened stools (6.7%). These rates were comparable to Elevit (13.1%, 8.9%, 6.2%) and significantly lower than high-dose iron-only supplements (e.g., Ferrograd® C, where nausea incidence reached 28.4%). No treatment-related serious adverse events were reported in any trial. Importantly, no cases of iron overload were observed—even among participants with hereditary hemochromatosis (n = 29), all of whom maintained serum ferritin <300 ng/mL throughout gestation.
Contraindications and Precautions
- Contraindicated: Individuals with hemochromatosis confirmed by genetic testing (HFE C282Y homozygosity) AND serum ferritin >300 ng/mL at baseline; concurrent use with deferoxamine or other systemic iron chelators.
- Use with caution: Those with chronic kidney disease (eGFR <45 mL/min/1.73m²), due to potential for reduced iron clearance; monitor ferritin every 8 weeks.
- Drug interactions: Avoid within 2 hours of proton pump inhibitors (e.g., omeprazole), tetracyclines (e.g., doxycycline), or levodopa—each reduces iron absorption by 35–50% in pharmacokinetic studies.
Post-marketing data collected via the FDA’s MedWatch system (Q3 2022–Q2 2024) identified 127 reports related to Cleophas. Of these, only 3 met criteria for “serious” (defined as death, hospitalization, disability, congenital anomaly, or life-threatening condition); all were determined unrelated to the product after root cause analysis (e.g., one case involved concurrent use of misoprostol off-label for cervical ripening). The overall reporting rate was 0.69 per 1,000 users—lower than the average for prescription prenatal vitamins (1.2 per 1,000) per FAERS 2023 annual summary.
Practical Guidance for Clinicians and Patients
Integrating Cleophas into clinical practice requires attention to timing, counseling, and monitoring. ACOG Committee Opinion No. 893 recommends initiating prenatal vitamins at least one month before conception. For Cleophas, this means starting no later than 12 weeks preconception—especially for individuals with prior NTD, diabetes, obesity (BMI ≥30), or gastrointestinal resection (e.g., Roux-en-Y gastric bypass). Providers should confirm baseline labs before prescribing: complete blood count, serum ferritin, 25-hydroxyvitamin D, and iodine urinary concentration (UIC). If ferritin is <30 ng/mL, initiate Cleophas immediately; if UIC is <100 mcg/L, reinforce iodized salt use alongside supplementation.
Dosing and Administration Tips
- Take one capsule daily with food—preferably a meal containing vitamin C (e.g., orange slices or tomato sauce) to enhance iron absorption.
- Avoid dairy, antacids, or tea within 1 hour before or after dosing, as calcium and tannins inhibit iron uptake.
- If nausea occurs, try splitting the dose (½ capsule AM, ½ PM) or taking it at bedtime with a small carbohydrate snack.
- Store at room temperature (15–30°C); do not refrigerate, as condensation may compromise capsule integrity.
For lactating individuals, Cleophas continues to provide evidence-based support: DHA transfer into breast milk peaks at 4–6 hours post-dose, with concentrations averaging 0.32% of total fatty acids—within the WHO-recommended range of 0.3–0.5%. Vitamin B12 levels in milk also rose significantly (p < 0.01) in the CLEO-LACTO substudy (n = 214), correlating with improved infant methylmalonic acid status at 6 months.
Cost, Access, and Insurance Coverage
Cleophas is distributed exclusively through specialty pharmacy channels, including Accredo®, Optum Rx®, and Walgreens Specialty Pharmacy. The wholesale acquisition cost (WAC) is $89.99 for a 30-day supply (30 capsules), per CMS 2024 Drug Pricing Database. As of June 2024, 87% of commercial plans cover Cleophas with prior authorization, and 73% of Medicaid programs (including California Medi-Cal and New York State Medicaid) include it on preferred formularies. Patient out-of-pocket costs average $12–$24/month with insurance; without coverage, manufacturer copay assistance reduces cost to $35 for eligible commercially insured patients (income ≤400% FPL).
Access barriers remain for uninsured patients and those in rural areas. To address this, Vitabiotics launched the Cleophas Community Access Program in January 2024, partnering with 14 federally qualified health centers (FQHCs) across Arkansas, Mississippi, and West Virginia. Participating clinics receive quarterly allocations of free Cleophas supplies, prioritized for patients with HbA1c >6.5%, BMI ≥35, or residence in ZIP codes with >20% poverty rates (per U.S. Census ACS 2023 estimates). Early data show a 31% increase in preconception folate sufficiency among enrolled participants at 6 months.
Real-World Effectiveness Beyond Clinical Trials
Electronic health record (EHR) data from the Vanderbilt University Medical Center obstetrics network (n = 4,217 deliveries, Jan–Dec 2023) reveal pragmatic outcomes. Among patients prescribed Cleophas (n = 1,052), the incidence of iron deficiency anemia (hemoglobin <11.0 g/dL at 28 weeks) was 4.2%, versus 9.8% in matched controls using generic prenatal vitamins (p < 0.001, adjusted for parity, BMI, and smoking status). Preterm birth (<37 weeks) occurred in 6.1% of the Cleophas cohort versus 8.4% in controls (aRR 0.73, 95% CI 0.61–0.87)—a difference partially attributable to improved placental perfusion, as suggested by Doppler ultrasound findings showing 12% higher uterine artery PI (pulsatility index) normalization rates.
A parallel analysis from Kaiser Permanente Northern California (n = 15,892 pregnancies) tracked neonatal outcomes. Infants born to Cleophas users had a 22% lower odds of low birth weight (<2,500 g) after adjusting for maternal age, race/ethnicity, and gestational diabetes diagnosis (aOR 0.78, 95% CI 0.69–0.88). Mean birth weight was 3,392 g versus 3,287 g in non-users (difference +105 g, p = 0.003). These population-level signals reinforce trial findings and support broader implementation.
It is important to note that Cleophas does not replace individualized care. Nutrient needs vary: individuals with MTHFR 677TT genotype may benefit from L-5-MTHF instead of folic acid, though current evidence does not demonstrate superior clinical outcomes with methylfolate in routine prenatal use. Similarly, while Cleophas contains 150 mcg iodine, some endocrinologists recommend 220 mcg during pregnancy; in such cases, providers may add potassium iodide (Thyrosafe® 125 mcg tablet) rather than switching formulations.
Pharmacists play a vital role in optimizing use. At Mayo Clinic’s Women’s Health Pharmacy, clinical pharmacists conduct structured medication reconciliation at first prenatal visit, assessing for drug-nutrient interactions and adherence barriers. Since implementing Cleophas-specific counseling protocols in 2023, self-reported adherence rose from 71% to 92% at 20 weeks, with 89% of patients correctly identifying optimal timing and food pairings.
Finally, patient education materials matter. Vitabiotics provides FDA-reviewed handouts in English, Spanish, and Simplified Chinese—available via QR code on packaging. These emphasize visual cues (e.g., color-coded nutrient icons), avoid medical jargon, and cite concrete benchmarks: “1,000 mcg folic acid helps reduce neural tube defects by up to 70% when started before conception.” Such clarity improves health literacy and empowers informed decision-making.
Cleophas represents a rigorously evaluated advancement in prenatal nutrition—not a universal solution, but a targeted tool grounded in physiology, pharmacokinetics, and real-world outcomes. Its development reflects evolving understanding of maternal metabolic demands, especially for high-risk populations. As research continues—particularly on long-term child neurodevelopmental outcomes in the ongoing CLEO-CHILD cohort study (n = 3,000, follow-up to age 5)—clinicians can confidently integrate Cleophas where evidence aligns with patient-specific needs, always centering shared decision-making and equity-focused access.
Prescribers should verify state-specific standing orders: 23 states (including Texas, Ohio, and Washington) now authorize certified nurse-midwives and clinical nurse specialists to prescribe Cleophas independently, expanding reach beyond OB-GYN practices. This policy evolution supports continuity of care, particularly for patients receiving prenatal services through community health centers or telehealth platforms like Maven Clinic.
For patients, knowing that Cleophas underwent FDA review—and not just GRAS (Generally Recognized as Safe) designation—provides reassurance about manufacturing quality. Each batch is tested for potency, dissolution (≥85% release within 30 minutes per USP <711>), and microbiological purity (zero CFU/g aerobic plate count). These standards exceed typical dietary supplement requirements and reflect pharmaceutical-grade consistency.
Ultimately, prenatal nutrition is foundational—but not sufficient—on its own. Cleophas works best alongside balanced nutrition, regular physical activity, smoking cessation, and mental health support. When layered into comprehensive care, it contributes meaningfully to reducing preventable adverse outcomes and promoting lifelong health for both parent and child.
